Biogen and Eisai are collaborating on the development of Leqembi, targeting early approval and market entry in key European markets like Austria and Germany.
1 report, 1 independent
Updated Sep 2
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Biogen and Eisai are collaborating on the development of Leqembi, targeting early approval and market entry in key European markets like Austria and Germany.
Who's involved
What this event is mainly aboutKeep exploring
Part of
Major pharmaceutical companies including Sanofi, Regeneron, Roche, Eli Lilly, Biogen, and Gilead are maintaining alliances and competing across key therapeutic areas like ophthalmology, immunology, and oncology.Also in this story
- Skyclarys announced its international expansion into Brazil and the U.K. on July 22, 2025.
- Organon acquired U.S. rights to TOFIDENCE from Biogen and laid off employees at its Jersey City headquarters.
- Biogen enhances patient outcomes through key drugs and therapies, while NIH studies reveal global incidence of ALS and CDC projects rising patient numbers in the U.S.
- Sooin was appointed Chief Business and Strategy Officer at Galapagos, which also announced a partnership with Gilead.
The entities involved
-
Biogen
American multinational biotechnology company
Nothing else this week.
-
Eisai (South Korea)
company in Seoul, South Korea
Nothing else this week.
Coverage
Newest first; wire copies grouped- Insider MonkeyBiogen Inc. (BIIB)’s Alzheimer’s Drug Leqembi Wins EU Nod, Now Approved in 48 Countries We recently compiled a list of the 10 High Growth Pharma Stocks That Are Profitable in 2025. Biogen Inc. is one